Bristol-Myers Squibb Company (BMY) stock prices updated...
 

Bristol-Myers Squibb Company stock price, BMY

Bristol-Myers Squibb Company stock chart:



Bristol-Myers Squibb Company close price: 55.03

Stock price forecast:

UP TO +0.29%
Target: 55.19

Total forecasts: 82
Reached: 28 (34.15%)

Total Win: 34.89 (63.31%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
90832934.94%36.850.81%2,974.45-12.89-0.43%23.960.52%
303100.00%0.000.00%1,705.87-0.06-0.00%-0.06-0.00%
141500.00%0.000.00%825.870.420.05%0.420.05%
7800.00%0.000.00%440.240.000.00%0.000.00%

Showing 1-10 of 436 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-05-2355.0355.190000-00-00
2017-05-2255.0354.950000-00-00
2017-05-2155.0354.970000-00-00
2017-05-2055.0354.960000-00-00
2017-05-1955.0354.960000-00-00
2017-05-1855.0354.880000-00-00
2017-05-1755.0355.060000-00-00
2017-05-1655.0355.060000-00-00
2017-05-1555.0354.460000-00-00
2017-05-1455.0353.620000-00-00

Bristol-Myers Squibb Company latest news:


  • 04/21/2017 12:19:56

    BRIEF-Bristol-Myers gets positive CHMP opinion recommending approval of Opdivo for treatment of a type of bladder cancer

    * Bristol-Myers Squibb receives positive CHMP opinion recommending approval of Opdivo (Nivolumab) for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer

  • 04/03/2017 09:07:05

    Bristol-Myers Squibb says cancer drug combination 'significantly' improved survival in late-stage melanoma trial

    Bristol-Myers Sqibb Co. said Monday morning that the combination of its two cancer drugs showed the best survival rates in melanoma patients in a late-stage clinical trial. The combination of the drugs Opdivo and Yervoy is one many Wall Street analysts believe is promising. Two-year overall survival rates for patients with previously untreated advanced melanoma were highest for the combination treatment, or 64%, followed by 59% for Opdivo alone and 45% for Yervoy alone, according to the company. The phase 3 trial enrolled 945 patients, and had a minimum follow-up period of 28 months. Bristol-Myers said that the clinical trial was not designed to compare Opdivo in combination with Yervoy with Opdivo alone, but that analyses found a relative reduction in death risk of 12% for the combination treatment, with risk of death reduced especially for patients with the PD-L1 biomarker of less than 1%. That's an important distinction, said EvercoreISI analyst Umer Raffat, who said the findings could have implications for an ongoing lung cancer trial. "Could the [Opdivo and Yervoy] combo have a better shot in the

  • More trends:

    Bristow Group IncBRS | Brixmor Property Group Inc.BRX | Broadridge Financial SolutionsBR | Brookdale Senior Living Inc.BKD | Brookfield Asset Management IncBAM | Brookfield Canada Office PropertiesBOXC | Brookfield DTLA Inc.DTLA^ | Brookfield Global Listed Infrastructure Income FunINF | Brookfield High Income Fund Inc.HHY | Brookfield Infrastructure Partners LPBIP |